Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2022-09-19 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于2022年限制性股票激励计划授予结果公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of a 2022 restricted stock incentive plan grant by the company. It details the number of shares granted, the recipients, the grant date, the lock-up and unlocking conditions, and the impact on the company's share capital structure. It also includes information about the use of funds raised and the accounting treatment of the stock-based compensation expense. The document is a formal announcement of the stock incentive grant results rather than a full financial report or audit. It does not contain comprehensive financial statements or quarterly/annual financial results. The content fits best under a category related to capital changes or share issuance due to the stock incentive plan and share registration. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is about 4867 characters, which is sufficient for a detailed announcement but not a full report. No indication that this is a report publication announcement or regulatory filing only. Hence, classification as SHA is appropriate with high confidence.
2022-09-19 Chinese
健民集团关于股份性质变更暨2022年限制性股票激励计划权益授予的进展公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the progress of a restricted stock incentive plan, specifically about the change in the nature of shares and the granting of restricted stock to certain incentive recipients. It includes details about the number of shares granted, the source of shares (repurchased shares), and the change in share structure. The document is relatively short (1342 characters) and is an announcement of a corporate action related to share capital and stock incentives. It does not contain full financial statements or detailed financial performance data. Therefore, it is best classified as a Share Issue/Capital Change announcement (SHA).
2022-09-14 Chinese
健民集团监事会关于2022年限制性股票激励计划激励对象名单（截止授予日）的核查意见
Regulatory Filings Classification · 90% confidence The document is a supervisory board opinion on the verification of the list of incentive recipients under the 2022 restricted stock incentive plan. It discusses compliance with laws and regulations regarding the eligibility of incentive recipients and confirms the granting of restricted stock to certain individuals. The document is not a financial report, earnings release, or regulatory filing about financial results. It is also not an announcement of voting results or a proxy statement. It relates to management and governance matters concerning stock incentives but does not detail compensation amounts or executive remuneration specifically. The document is a formal opinion from the supervisory board on the incentive plan participants, which fits best under the category of Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories like Remuneration Information or Share Issue/Capital Change. The document length is short and it is a formal statement rather than a full report or presentation.
2022-09-05 Chinese
健民集团第十届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the first meeting of the tenth board of directors of the company. It details the election of the chairman, appointment of senior management including president, vice presidents, financial director, and board secretary, as well as approval of contracts and stock incentive plans. The content focuses on board and senior management changes and appointments. There are no financial statements or detailed financial performance data. The document is not a full annual or interim report, nor an earnings release. It is not a proxy statement or voting results announcement. The document fits the category of Board/Management Information (MANG) as it announces changes and appointments in the company's board and senior management.
2022-09-05 Chinese
健民集团2022年限制性股票激励计划截止授予日的授予名单
Capital/Financing Update Classification · 95% confidence The document is a list of recipients and quantities for a 2022 restricted stock incentive plan, detailing stock grants to company executives and key personnel. It includes specific share numbers and percentages of total share capital. This is an announcement related to share-based compensation and stock incentives, which typically falls under capital or financing updates. It is not a full financial report, audit, or management discussion, nor is it a voting result or director dealing report. The document is short and focused on stock grants, so it fits best under Capital/Financing Update (CAP).
2022-09-05 Chinese
健民集团关于聘任高级管理人员等的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of senior management personnel at the company, including the president, vice presidents, financial director, board secretary, and securities affairs representative. It details the qualifications, terms, and independent directors' opinions on these appointments. There is no financial data, earnings information, or report content. The document is clearly about management changes and appointments, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on personnel appointments, confirming it is not a full report or other filing type.
2022-09-05 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.